despite its massive potential and widespread usage. FMT is a personalized procedure where stool is collected from a donor, processed and placed in a patient to replace the beneficial bacteria that have either been killed or suppressed. This is currently effective in the treatment of dysbiosis caused by Clostridium difficile. FMT have been shown to have 90% efficacy with the first round of treatment. Compare this to the 84% efficacy of first-round treatment of C. difficile through antibiotic treatment and the 40% efficacy of antibiotic treatment after multiple relapses. Secondly, personalized culture collections are communities of microbes that can be selected from cultures based on specific criteria. These molded cultures can be inserted into
…show more content…
Another company, Evolve Biosystems, is looking to the correlation of respiratory, GI and hyper allergenic disorders with the existing microbiome in babies, which is directly obtained from their mothers. Evolve is looking to develop an effective probiotic bacterium that can be activated with prebiotic oligosaccharides to maintain healthy microbiomes in newborns3. Current microbiome treatment through FMT has been left to gastroenterologists. Because the microbiome has a substantial presence in the gut, gastroenterologists will be entering this field, but also other specialties of organ systems can be expected such as immunologist, dermatologists, and even neurologists where microbiomes also exhibit effect. Much of the technology being developed is geared towards physicians and the majority of the products targeting specific organisms in the microbiome will remain the job of the physicians. This is true because FMT and other transplant therapies are procedures that can only be performed in a medical setting. Secondly, patients have little knowledge on the effective and efficient usage of microbiome technologies. However, products such as dietary probiotics and preventive bacterial supplements are easily marketable to consumers. While currently FMT is
Another company, Evolve Biosystems, is looking to the correlation of respiratory, GI and hyper allergenic disorders with the existing microbiome in babies, which is directly obtained from their mothers. Evolve is looking to develop an effective probiotic bacterium that can be activated with prebiotic oligosaccharides to maintain healthy microbiomes in newborns3. Current microbiome treatment through FMT has been left to gastroenterologists. Because the microbiome has a substantial presence in the gut, gastroenterologists will be entering this field, but also other specialties of organ systems can be expected such as immunologist, dermatologists, and even neurologists where microbiomes also exhibit effect. Much of the technology being developed is geared towards physicians and the majority of the products targeting specific organisms in the microbiome will remain the job of the physicians. This is true because FMT and other transplant therapies are procedures that can only be performed in a medical setting. Secondly, patients have little knowledge on the effective and efficient usage of microbiome technologies. However, products such as dietary probiotics and preventive bacterial supplements are easily marketable to consumers. While currently FMT is